The aim of the study was the identification of a pharmacogenetic profile predictive of the tumor regression grade (TRG), considered as tumor response parameter, after neo-adjuvant treatment in rectal cancer patients. A total of 238 rectal cancer patients treated in a neo-adjuvant setting by a fluoropyrimidines-based chemo-radiotherapy (RT) were genotyped for 25 genetic polymorphisms in 16 genes relevant for treatment-associated pathways. Two polymorphisms were associated with TRG in a multivariate analysis: hOGG1-1245C4G, which can affect radiosensitivity and MTHFR-677C4T, which is involved in fluoropyrimidines action. Patients bearing at least one variant allele had a lower chance to get TRGp2 (OR ¼ 0.46 95% CI 0.23-0.90, P ¼ 0.024; and OR ¼ 0.48 95% CI 0.24-0.96, P ¼ 0.034; respectively). An association trend was observed for ABCB1-3435C4T, which is responsible for the multi-drug resistance (odds ratio (OR) ¼ 1.96, 95% confidence interval (CI) 0.98-3.95, P ¼ 0.057). Exploratory classification and regression tree (CART) analysis highlighted high-order gene-gene and gene-environment interactions and a genetic signature associated with differential response, with hOGG1-1245C4G as the most predictive factor. Other significant variables were: ABCB1-3435C4T, MTHFR-677C4T, ERCC1-8092C4A, ABCC2-1249G4A, XRCC1-28152G4A, XRCC3-4541A4G and patients gender. On the basis of CART results, patients were categorized into three groups according to tumor response probability: intermediate and high profiles had a higher probability to get TRGp2 as compared with low profiles (OR ¼ 4.12 95% CI 1. Po0.001 and OR ¼ 12.44, Po0.0001, respectively). This study evidences a major role of hOGG1-1245C4G and MTHFR-677C4T polymorphisms in the tumor response of rectal cancer patients treated with chemo-RT in neo-adjuvant setting, and shows the relevance of gene-gene and gene-environment interactions for complex phenotypes as tumor response.
Introduction
Preoperative chemo-radiotherapy (pCRT) or short-course radiotherapy (RT) followed by total mesorectal excision is considered standard of care for locally advanced mid-low rectal cancer. Using the pCRT approach, the rate of local recurrence at 5-year ranges from 6 to 8%, 1, 2 and the rate of complete pathological response ranges from 4 to 44% of cases, as reported in single institution series trials, 3, 4 in phase II studies [5] [6] [7] and in randomized trials. 2, 8 For patients with good pathologic response to pCRT, the oncological outcome has been reported to be better for 'responders' than for 'nonresponders'. 9, 10 In addition, the tumor regression grade (TRG) characterization of the pathologic response has shown to be a prognostic factor for local failure, metastasis-free and overall survival with significant better outcome for patients reporting TRG 1-2 (absence or scattered residual isolated cancer cells) compared with those reporting TRG 3-5 (increase in the number of residual cancer cells). 11, 12 Nonetheless, TRG 3 could be considered an intermediate prognostic status and some investigators suggested a three-point classification system (TRG 1-2, TRG 3 and TRG 4-5) as a good predictor of pCRT outcome in rectal cancer. 13 For patients with pathologic complete response after pCRT, some investigators advocate an observational approach without any surgical treatment, 14 and others suggest that the transanal local excision may be appropriate. 15 On the basis of these considerations, it seems clinically relevant to understand which factors within the tumor predict high sensitivity to the neo-adjuvant regimen and what determines resistance, as this knowledge may permit tailor-made individualization of therapy. In fact, neo-adjuvant treatment followed by standard surgery is time consuming, expensive and increases perioperative morbidity. 8, 16 Host genetic variability has been recently shown to represent a key component in the personalization of cancer chemo-radiation particularly in the neo-adjuvant treatment of locally advanced rectal cancer. [17] [18] [19] A majority of the pharmacogenetic studies focus on a single candidate gene, which is assumed to be strongly associated with the clinical outcome of the drug. Recently, a more comprehensive approach that takes into account the complex interplay of different metabolic and cellular pathways involved in an association therapy has been adopted.
In this study, we used a pathway-based approach and selected 25 polymorphisms in 16 different genes having a key role in rectal cancer pCRT, and in particular in radiation (XRCC1, XRCC3, ERCC1, ERCC2, RAD51, hMLH1, hMSH2, hOGG1, GSTP1, GSTT1, GSTM1 and GSTA1 genes), fluoropyrimidines (TYMS and MTHFR genes) and multi-drug resistance (ABCB1 and ABCC2 genes) related pathways. We evaluated their individual association with TRG and the high-order gene-gene and gene-environment interactions between these factors using classification and regression tree (CART) analysis. The aim of the study was to identify a specific genetic profile predictive of the TRG, as the most widely recognized parameter of tumor response, in locally advanced rectal cancer patients treated with pCRT.
Patients and methods

Study design and patients enrollment
Between December 1993 and June 2006, 277 consecutive mid and low primary rectum adenocarcinoma patients undergoing pCRT were enrolled at the CRO-National Cancer Institute of Aviano, Italy (106 patients) and at the General Hospital of Padova University Medical School, Padova, Italy (171 patients). The pretreatment evaluation of patients included a complete clinical history and physical examination, colonoscopy, complete blood cell count, chest X-ray, hepatic and transrectal ultrasound, pelvic computed tomography scan and carcino-embryonic antigen test. All procedures were reviewed and approved by the institutional review board of each participating institution, and all patients signed a written informed consent for research purposes before entering this study. Thirty-nine patients were not eligible in the study because they did not undergo radical surgery or they were affected by metastatic disease. Tumor and patients characteristics are described in Table 1a .
Radio-chemo-surgery Chemoradiation and surgical treatments have been described elsewhere (Table 1b) . 6, 20 In brief, patients underwent to external beam RT with a 10-18 MV linear accelerator. The clinical target volume included the primary tumor, with the mesorectum, the posterior walls of the bladder and prostate/vagina, and the internal iliac nodes. A three or fourshaped field box technique was used. A radiation dose of 45-50.4 Gy (according to the consecutive study protocols used in the period time considered for the analysis) was given, with a conventional fractionation of 1.8 Gy per day, 5 days a week.
Chemotherapy consisted of a fluoropyrimidine (mainly 5-fluorouracil (5-FU)) alone or in combination with other drugs (platinum derivatives, irinotecan or gefitinib). In a subset of patients raltitrexed was used in substitution to 5-FU (Table 1b) . Variations in preoperative therapy were related to (a) the period of treatment (during the initial years of the study 5-FU bolus was used in combination with lowdose leucovorin and external beam RT, 45 Gy in 25 fractions, and later 5-FU was administered by continuous venous infusion and external beam RT, 50.4 Gy in 28 fractions); (b) the enrollment of patients in prospective clinical trials.
Therapy efficacy assessment
Radicality of the surgical procedure and tumor, node and metastasis staging was reported following the American Joint Committee on Cancer Tumor, Nodes and Metastasis (TNM) classification. 21 The whole residual tumoral area was sampled for histopathological examination and histopathological tumor-staging after radiotherapy (ypT) assessment. Mesorectal surgical margin status and lymph nodal changes were described in the pathological reports. The pathological tumor response to preoperative therapy was adapted from the TRG criteria suggested by Mandard et al. 22 for esophageal carcinoma: TRG-1, pathologic complete response; TRG-2, presence of residual cancer cells scattered through the fibrosis; TRG-3, fibrosis outgrowing residual cancer cells; TRG-4, residual cancer cells outgrowing fibrosis; and TRG-5, absence of regressive changes.
Genotyping assays
Genomic DNA was extracted from peripheral blood using the High Pure PCR Template Preparation Kit (Roche Diagnostics GmbH, Mannheim, Germany), the Talent kit (Talent, Trieste, Italy), QiaAmp DNA Mini Kit (Qiagen, Valencia, CA, USA) and the DNeasy Tissue Kit (Qiagen) for DNA extraction from paraffin-embedded tumor tissue in 49 samples. Positive controls were included in the analyses.
Pyrosequencing (Biotage, Uppsala, Sweden) was used for the analysis of:
(rs13181), ERCC2-23591G4A (rs1799793). PCR amplifications were performed in a Eppendorf Mastercycler gradient, with TaqGold DNA Polymerase (AB Applied Biosystems, Warrington, UK). The detail of pyrosequencing assays, primer sequences and PCR conditions are available on request.
Pre-designed Taq Man SNP genotyping assays with the Applera TaqMan Universal Master mix were used on ABI 7900HT (AB Applied Biosystems, Foster City, CA, USA) according to the manufacturer's instructions for the discrimination of the following SNPs:
GSTT1 and GSTM1 null genotypes and the TYMS 28bpVNTR (rs34743033) were analyzed by PCR coupled with agarose gel electrophoresis. 23, 24 TYMS del6bp1494 (rs16430) was analyzed by PCR-restriction fragment length polymorphism. 24 The haplotype assessment was performed using Phase 1.0 available on http://www.pharmgat.org ''Pharmacogenetics of asthma treatment website''.
Statistical analysis
TRG was used as the response parameter. Patients were split into three groups expected to have a significantly different therapy outcome on the basis of their TRG. According to literature data, 13, 25 patients with TRG 1-2 were considered as good responders, those with TRG 3 were considered as intermediate responders, whereas patients with TRG 4-5 were considered as non-responders. The association between patients' clinico-pathological and demographic characteristics and genotypes and TRG was tested first by univariate Fisher's exact test and by w 2 test for trend. A logistic regression model was subsequently applied for TRG investigation. Patients characteristics, selected as significant by univariate analysis (Po0.05 cut-off), were included in a stepwise logistic regression analysis in the multivariate model. Odds ratios (ORs) and 95% confidence intervals (CIs) were computed.
The potential high-order gene-gene and gene-environmental relationships among the discriminating factors were further analyzed comparing the responders (TRG 1-2) with the non-responders (TRG 4-5) groups of patients. In particular, a CART method, based on recursive partitioning was applied. Recursive partitioning is a technique that can be used to mine large data sets to uncover hidden patterns within the data and to elucidate statistically significant subgroupings. The process starts with the root node that contains all the good responders (TRG ¼ 1-2; n ¼ 122) and the non-responders (TRG ¼ 4-5, n ¼ 65) subjects. It finds the A total of 54 patients underwent association preoperative chemotherapy (platinum derivatives in 44 patients, gefitinib in 7 patients and irinotecan in 3 patients were associated with either fluoropyrimidines or raltitrexed).
split with the smallest P-value for the root node and each subsequent node generating a 'decision tree', in which the data that are more similar according to some criteria tend to be localized into the same nodes. Univariate analyses were performed using the GraphPad InStat software (GraphPad Software, La Jolla, CA, USA), whereas for CART analysis 'R' statistical package version 2.6.2 was used (R is a free software environment developed at Bell Laboratories (formerly AT&T, now Lucent Technology) by John Chambers and colleagues (http://www.r-project.org)).
Owing to the exploratory nature of this study, no P-value adjustments were made for multiple hypotheses testing. A Po0.05 indicated a lack of agreement with Hardy-Weinberg equilibrium evaluated by a permutation procedure based on an exact test.
Results
Association of TRG with clinical/demographic characteristics and germline polymorphisms by univariate analysis Genomic DNA samples were obtained from blood or tumor tissue samples of 238 Caucasian eligible patients. Median follow-up of the study was 49.3 months (range, 0.9-164.5 months). During this period 41 deaths occurred (17.2%).
Gender (male/female), tumor location (p7/47 cm from the anal verge), preoperative clinical T stage (2/3-4), fluoropyrimidines administration (yes/no), radical surgery (yes/no) and total RT dose delivered (45.0/50.4 Gy) were considered for univariate association with the TRG. None of these resulted significantly predictive of TRG, though a nonsignificant trend (Po0.10) for a worse TRG was found for patients presenting a minimal tumor residual after surgery ( Table 2 ).
The genotyping procedure was successful in a mean of 230 patients out of 238 (mean call rate 95.6%, range: 90.3-100.0%): this is due to the quality of the biological samples (the highest percentage of genotyping failure regarded genomic DNA from paraffin-embedded tumor samples, with a mean call rate of 86.9%, range: 55.3-100.0%). Genotypes frequencies were determined for all the polymorphisms considered. No Hardy-Weinberg disequilibrium was observed (P40.05). A haplotype analysis was performed for the genes with multiple polymorphisms testing. The w 2 test for trend indicated a significant association among the three Tables 4 and 6 ). For MTHFR and ABCB1 genes, the haplotype joint analysis did not add any predictive value in comparison with the single polymorphism approach (Tables 3 and 6 ). None of the genetic variants considered was a significant discriminating marker between good responders (TRG 1-2) and intermediate responders (TRG ¼ 3) (Tables 3-6 ).
The application of the w 2 test for trend highlighted a significant trend for ABCB1-3435C4T (P ¼ 0.046), hOGG1-1245C4G (P ¼ 0.029) and MTHFR-677C4T (P ¼ 0.045) polymorphisms only.
Association of TRG with clinical/demographic characteristics and germline polymorphisms by multivariate analysis hOGG1-1245C4G and MTHFR-677C4T polymorphisms were significant predictors (Po0.05) of TRG (TRGp2 vs . ABCB1-3435C4T maintained only a nonsignificant association trend with TRG in the multivariate analysis (P ¼ 0.057) ( Table 7) .
Association of TRG with clinical/demographic characteristics and germline polymorphisms by recursive partitioning analysis
Recursive partitioning was applied to further elucidate genegene and gene-environmental relationships between good responders (TRGp2) and non-responders (TRGX4). The analysis allowed the identification of 10 subgroups of patients according to genotypes and clinical/demographic characteristics with different probability to develop a TRGp2 (Figure 1 ). In Figure 1 , each box is called a 'node' and represents a subset of the observations in the entire data set. As there is one missing data in the genotypes combination, the sum of the observations in the daughter nodes corresponds to 186 instead of 187, as reported in the parent node. Each terminal (not partitioned) node is characterized by a unique combination of marker genotypes and the percentage of patients experiencing TRGp2 in each terminal node is reported. 
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All the 25 germline polymorphisms analyzed as well as the clinical and demographic characteristics were included in the model. The first node of the tree is determined by the hOGG1 polymorphism discriminating two groups: -1245CG or -1245GG vs -1245CC. Patients with the hOGG1-1245CG or -1245GG genotypes are further split based on the ERCC1-8092C4A polymorphism defining group 1 (77% of chance to get one or two TRG for -8092CC genotype) and group 2 (31% of response for -8092CA or -8092AA genotypes). For patients with the hOGG1-1245CC genotype, further discriminating polymorphisms were MTHFR-677C4T, ABCB1-3435C4T, ERCC1-8092C4A, XRCC1-28152G4A, ABCC2-1249G4A and XRCC3-4541A4G. The patients gender too was found to act as a discriminator, with a higher percentage of TRGp2 among male patients. The terminal nodes were categorized in three risk groups based on the case ratio: the low (ratiop40%), the medium (40%oratioo70%) and the high-probability group (ratioX70%). Three of them are in the low-probability group (14 to 31% chance to get a TRGp2), two have intermediate-probability (54 and 67%) whereas five groups are in the high-probability group (77-93%). By Fisher's exact test the three groups resulted highly significantly associated with TRG (TRGp2 vs TRGX4) ( Table 8) .
Discussion
A high inter-individual variability in terms of therapy efficacy and toxicity could limit the use of pCRT in rectal cancer. In this study, with a candidate pathway-based strategy, we succeeded in defining a combination of genetic markers associated with a differential probability to get benefit from the treatment, in terms of TRG. The major finding of the study is the identification of two genetic polymorphisms that resulted associated by multivariate analysis to tumor response: hOGG1-1245C4G and MTHFR-677C4T. This suggests a role of two different cellular pathways on the response to a fluoropyrimidinesbased chemo-radiation treatment: the DNA repair (hOGG1) that is important for response to radiation; and the folate cycle (MTHFR), which is known to affect the fluoropyrimidines pharmacological effect. A marginal effect could be attributed also to the cellular transport (ABCB1), responsible for the multi-drug resistance, because a border line association in the multivariate approach, has been found for the ABCB1-3435C4T polymorphism (P ¼ 0.057). In a further attempt to test high-order gene-gene and gene-environment interactions, useful when examining complex phenotypes as tumor response, as recently suggested by the Pharmacogenetics Research Network Group 26 we performed a CART analysis comparing good responding patients (TRGp2) with non-responders (TRGX4). This approach confirmed the most prominent role of hOGG1-1245C4G polymorphism as the most discriminating factor and successfully defined a distinctive polymorphic signatures grouping the subjects according to different response probability, with MTHFR-677C4T and ABCB1-3435C4T as relevant variables with ERCC1-8092C4A, XRCC1-28152G4A, XRCC3-4541A4G, ABCC2-1249G4A and patients gender.
hOGG1-1245C4G polymorphism emerged as the most important discriminating factor for tumor response, and the variant allele hOGG1-1245G was associated with a worse TRG. hOGG1 protein belongs to the base excision repair pathway and is involved in the DNA repair after exposure to ionizing radiation. hOGG1-1245C4G polymorphism is associated with the production of a low-functional protein, nonetheless the phenotypic effect of the polymorphism on the RT outcome has not been elucidated yet. Some in vitro data reported that cell lines bearing hOGG1 polymorphism, and therefore with a lower expression of hOGG1 protein, showed an increased radiosensitivity. 27, 28 On the contrary, other studies highlighted that in case of radiation damage, Genetic polymorphisms predict response in rectal cancer E Cecchin et al the base excision repair does not always protect cells from biological consequences and a decreased hOGG1 expression level favors DNA repair efficacy after g-irradiation. The first step of base excision repair is catalyzed by the oxidative DNA glycosilase as hOGG1, which removes the altered purines or pyrimidines. A number of in vitro repair studies have shown that the processing of bistrand damage clusters by base excision repair enzymes may convert otherwise non-lethal, readily repairable or bypassable lesions into lethal double-strand breaks. 29, 30 These data support our findings that patients carrying the defective hOGG1-1245G allele, less prone to double-strand breaks production and thus less radiosensitive, present the worst therapy outcome.
MTHFR-677C4T, which has a key role in the folate cycle, was the other polymorphism significantly predictive of the treatment outcome by multivariate analysis. We noticed that patients with a variant allele had a worse TRG. MTHFR-677TT genotype, causing an increased availability of folate intermediates, was expected to enhance patients responsiveness to 5-FU 31, 32 though the influence of the polymorphism on the 5-FU pharmacological action is still Genetic polymorphisms predict response in rectal cancer controversial. 18, 33 We could hypothesize an opposite role of the polymorphism on the RT efficacy because of MTHFR critical role in DNA synthesis and repair. A reduced MTHFR activity, linked to the -677C4T polymorphism, could lead to an enhanced availability of non-methylated folate substrates for de novo synthesis of nucleotides, which could preserve DNA integrity, reducing uracil misincorporation, single-and double-strand breaks, DNA misrepair and genetic instability. 34 Patients with a wild MTHFR-677CC genotype could be more prone to DNA damage caused by ionizing radiation and thus be more sensitive to the therapy, though the effect of the polymorphism on ionizing radiation sensitivity appears to be related to micronutrients concentrations in vitro. 35 Further mechanistic studies are necessary to confirm this hypothesis and this predictive role of MTHFR-677C4T, as the others reported in this work should be interpreted with caution and further confirmed, because of the exploratory nature of the study.
The multifactorial nature of tumor response to chemo-RT and the complex interactions among the considered genetic and non-genetic factors, induced us to further analyze highorder gene-gene and gene-environment interactions. So traditional methods as logistic regression and contingency tables could not be appropriate because of the small number of observations and the sparseness of the data in this kind of studies, an exploratory CART analysis was applied. hOGG1-1245C4G polymorphism emerged as the strongest discriminating factor, consistently with the main findings of the study. We identified distinctive polymorphic signatures predictive of TRG. A majority of the genetic variants included in the regression tree are located in DNA-repair genes, highlighting a prominent role of the DNA-repair pathways in the response to the chemo-radiation treatment. Some of these genes belong to the cellular pathways responsible for the repair of DNA damage after ionizing radiation exposure: the base excision repair (hOGG1 and XRCC1) and the double-strand breaks repair (XRCC3). 36, 37 In contrast, ERCC1 gene, included in the nucleotide excision repair pathway, is mostly involved in the repair of bulky DNA adducts associated with the action of platinum derivatives. [38] [39] [40] Nonetheless, recent data highlighted that genetic polymorphisms of ERCC1 and of nucleotide excision repair pathway in general have an effect also on the therapeutic efficacy of RT. 41 The CART analysis pointed out an increased response chance to RT associated with the XRCC1-28152G4A polymorphism. Higher radio-sensitivity and favorable prognosis in individuals with the XRCC1-28152G4A variant had already been reported by other investigators. 40, 42 An inefficient removal of the DNA adducts after irradiation associated with the defective XRCC1-28152AA genotype, appears to cause an enhancement of radiation sensitivity. The XRCC3-4541A4G, a non-coding polymorphism in the 5 0 UTR of the gene, has a not clarified effect on protein expression. Our data suggest a protective role of the variant allele toward radiation injury, with decreased tumor response (TRGX4) in patients carrying the polymorphism. At our knowledge, no data are available up to date on the effect of XRCC3-4541A4G on tumor response to radiation. Some investigators reported an increased radiation-related toxicity associated with the polymorphism supporting a possible increased sensitivity to DNA damage in patients with the XRCC3-4541A4G polymorphism. 37 Nonetheless, a protective role of the XRCC3-4541G allele has been also described for breast tumor development, suggesting an improved cellular defense against DNA damage, mediated by the XRCC3 protein, in individuals with the polymorphism. 43 In fact the phenotypic effect of the polymorphism is still controversial and our preliminary results will need to be further confirmed. The variant ERCC1-8092AA genotype, related to differential expression level of the encoded protein, was associated with an unfavorable treatment outcome in this study. ERCC1 expression level was previously related to pharmaco-resistance to chemo-radiation regimens including platinum derivatives 39, 44 and recently to RT alone. 41 We highlighted a predictive role of ERCC1-8092C4A polymorphism on TRG, a parameter directly related to therapy efficacy, whereas most of the researches published analyzed the prognostic role of the protein expression on overall survival and time to progression. 39, 45, 46 ABCB1-3435C4T polymorphism in the gene encoding for the cellular transporter MDR1 (P-gp), and ABCC2-1249G4A are implicated in multi-drug resistance and emerged in our Genetic polymorphisms predict response in rectal cancer study as predictive variants. Several chemotherapeutic agents used (raltitrexed, platinum derivatives, irinotecan, gefitinib) represent a substrate for P-gp and ABCC2 supporting a possible enhanced exposure of patients carrying the defective polymorphisms to the therapeutic effect of the drugs. In particular, previous data 47 highlighted a reduced recurrence rate and an improved survival in esophageal cancer patients carrying the variant genotype ABCB1-3435TT after chemo-radiation treatment including platinum derivatives, as in a subset of the patients involved in this study. The role of this transporter on the platinum derivatives cellular accumulation and chemo-resistance has been previously shown in tumor cell lines hyper-expressing P-gp. 48 Patients gender in combination with a particular genetic profile could be an additional response marker, in line with recently reported sex-specific reaction to cancer chemotherapy both in terms of toxicity or efficacy. 49, 50 In summary, the complexity of tumor response to chemo-RT is reflected by the CART approach, nonetheless CART analysis is a machine-learning approach that uses available data to define a model. The interactions highlighted by this study should be verified and validated in independent studies. The encouraging results and the clinical relevance of the topic analyzed encourages further prospective investigation for markers validation. The inclusion of these markers into a pharmacogenetic predictive clinical model could result in the possibility to a priori classify those patients who would not benefit from a neo-adjuvant treatment to offer them an alternative treatment approach.
In this study, we decided to adopt a three-point classification system (TRGp2, TRG 3 and TRGX4) to split the patients into subgroups with significantly different prognosis, according to previous studies. 13 Two genetic markers were discovered to significantly discriminate between good (TRGp2) and poor (TRGX4) responders, whereas none of the analyzed polymorphisms was able to identify intermediate TRG 3 responders, though a significant trend was found among the three groups by the w 2 test. This exploratory finding could support a borderline situation of these patients either from a histo-pathologic or from a prognostic point of view, although further confirmatory studies could better elucidate this topic.
In conclusion, our results evidenced the need to perform pathway-based polygenetic studies to highlight the genetic effect on complex phenotypes as tumor response to treatment. There emerged a major role of two polymorphisms associated with the DNA repair (hOGG1), and to folate pathway (MTHFR). Our data also suggest that the effects of high-order interactions should be taken into consideration when evaluating tumor response to pCRT in rectal cancer patients. The possibility to identify patients with a differential response chance could help clinicians in therapy tailoring by including the use of more conservative procedures, such as local excision rather than radical surgery. This represents a particularly important issue for pCRT in rectal cancer, because the clear benefit of the treatment is at present limited by the high variability encountered among patients.
